Researchers look back at who gets new prostate cancer pill

NCT ID NCT06462014

Summary

This study looked back at the medical records of 507 veterans with prostate cancer who started taking the oral medication relugolix. The goal was to understand the types of patients who use this newer drug, their health characteristics, and their previous treatments. It did not test if the drug works or is safe, but instead gathered information on how it is being used in real-world medical practice.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Pfizer

    New York, New York, 10001, United States

Conditions

Explore the condition pages connected to this study.